|
Extended indication |
Patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy and whose disease is refractory to at least one PI, one IMiD, and one anti-CD38 monoclonal antibody, and to their most recent treatment regimen.
|
|
Therapeutic value |
No judgement |
|
Total cost |
€
6,640,000.00
This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. |
|
Registration phase |
Registration application pending |